Topline pivotal data expected in 2025 for both TKI pre-treated ROS1-positive and TKI pre-treated ALK-positive NSCLC populations First NDA submission planned for mid-year 2025 towards potential first approval in 2026 for zidesamtinib in TKI pre-treated ROS1-positive NSCLC population...
Read More Details
Finally We wish PressBee provided you with enough information of ( Nuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results )
Also on site :
- Surging travel in Europe spikes concerns over tourism's drawbacks
- Iran& 039;s key nuclear sites & 039;obliterated& 039; by US airstrikes, Trump says
- PRT vs PCC Dream11 Prediction Today Match, Dream11 Team Today, Fantasy Cricket Tips, Playing XI, Pitch Report, Injury Update- ECS T10 Czechia Premier 2025, Qualifier 1